Uncategorized

Novartis scraps mid-stage radiopharma asset as Pluvicto soars

Published

on

The discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version